Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition